Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States

Centralized Gulf States Survey on the Undertreatment of Hypercholesterolemia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01031277

Acronym

CEPHEUS

Enrollment

1000

Registered

2009-12-14

Start date

2009-11-30

Completion date

2010-07-31

Last updated

2011-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Keywords

Hypercholesterolemia, Update NCEP ATP111, Survey

Brief summary

The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country, to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III in the following sub-populations: * Primary/secondary prevention patients. * Patients with metabolic syndrome (according to NCEP III definition). And to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations: * Primary/secondary prevention patients. * Patients with metabolic syndrome.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Race * On lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks. * Subject must sign informed consent

Exclusion criteria

* Subjects who are unwilling or unable to provide informed consent.

Design outcomes

Primary

Measure	Time frame
To establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country.	6 months- One visit only, no follow up visits.

Secondary

Measure	Time frame
Proportion patients on lipid-lowering drugs (LLD) reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III in subgroups: Primary/secondary prevention patients; Patients with metabolic syndrome ( NCEP III).	6 months- One visit only, no follow up visits.
Proportion patients on LLD reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in sub-populations: Primary/secondary prevention patients; Patients with metabolic syndrome.	6 months- One visit only, no follow up visits.
To identify determinants (e.g. patient and physician characteristics, country-specific guidelines or recommendations) for undertreatment of hypercholesterolemia.	6 months- One visit only, no follow up visits.

Countries

United Arab Emirates

Outcome results